A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Takeda
Alaunos Therapeutics
Tempus AI
Incyte Corporation
Actym Therapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Ikena Oncology
Day One Biopharmaceuticals, Inc.
Alaunos Therapeutics
Mirati Therapeutics Inc.
Elevation Oncology
Kymab Limited
Biomea Fusion Inc.
Merck Sharp & Dohme LLC
The Netherlands Cancer Institute
Mirati Therapeutics Inc.
ABM Therapeutics Corporation
Rain Oncology Inc
Novartis
NantCell, Inc.
Maastricht University Medical Center
NantCell, Inc.
Pfizer
ADC Therapeutics S.A.
Ikena Oncology
Rutgers, The State University of New Jersey
pharmaand GmbH
Fate Therapeutics
Fate Therapeutics
Hoffmann-La Roche
Genmab
Montefiore Medical Center
MacroGenics
National Institutes of Health Clinical Center (CC)
Cambridge University Hospitals NHS Foundation Trust
Tocagen Inc.
National Institutes of Health Clinical Center (CC)
CureOne
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Cota Inc.
Western Regional Medical Center
Western Regional Medical Center
Masonic Cancer Center, University of Minnesota
New York State Psychiatric Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Par Pharmaceutical, Inc.
Amgen